We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.
In the early stages of the disease, this can result in mild symptoms such as reduced appetite or feelings of fatigue, but as CKD progresses, "complications like high blood pressure, heart disease ...
The size of the national population of patients with grown-up congenital heart disease (GUCH) is uncertain, but since 80–85% of patients born with congenital heart disease now survive to adulthood ...